Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan within 48 hours of brain tumor surgery could spot leftover cancer

NCT ID NCT07274397

Diagnosis Sponsor: Beta Emitting Accurate Monitored Systems Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special brain scan (PET-MRI) done within 48 hours after glioblastoma surgery is safe and practical. Fifteen adults who just had their first surgery for a suspected glioblastoma will get this scan, which uses a radioactive tracer and contrast dye. The goal is to see if this early scan can find leftover tumor better than standard MRI, without causing harm.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-DOPA radiotracer and gadolinium contrast
What this could lead to
If successful, this imaging method could help surgeons see remaining tumor more clearly right after surgery, guiding further treatment decisions.
What could go wrong
This is a very small, early feasibility study with only 15 patients, so results may not apply broadly. The imaging itself carries minor radiation exposure and contrast risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * First resection for a suspected glioblastoma in the past 72h * Signed informed consent non-inclusion Criteria: * Deprived of liberty or under legal protection (e.g, guardianship, trusteeship) * Patients under 18 years old * Absence of social security cover * Pregnancy * Emergency procedure * Contraindication to brain MRI, including claustrophobia * Contraindication to radiotracers or gadolinium injection * Preoperative cognitive impairment impeding patient information Exclusion criteria : * Any postoperative behavioral disorders or medical condition or symptom impeding the completion of brain imaging * Postoperative medical dependency impeding the patient transfer to the nuclear medicine department (including, but not limited to, invasive ventilation, need for external ventricular drainage…) * Postoperative histological diagnosis different from glioblastoma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain imaging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain imaging Brain tumors Glioblastoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Hôpital Henri Mondor - Université Paris-Est Créteil (UPEC)

    RECRUITING

    Créteil, 94010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.